Blab Business
Latigo Biotherapeutics Files for Nasdaq IPO, Aims to Bring Sodium-Channel Pain Drug to Market
Latigo Biotherapeutics Inc. announced on July 17 2026 that it has filed a registration statement with the U.S. Securities and Exchange Commission, setting the stage for an initial public offering that could raise up to $100 million and place the company on the Nasdaq Stock Market under the ticker symbol “LTGO.”
Founded in 2018 by venture‑capital firm Westlake BioPartners, the clinical‑stage biopharmaceutical focuses on non‑opioid pain medicines. Its flagship small‑molecule, LTG‑101, is a blocker of sodium ion channels and is slated to enter late‑stage (Phase 3) testing by the end of 2026 for moderate to severe acute pain. According to the S‑1, Latigo has raised roughly $322 million since its inception and, as of March 31, 2026, reported a cumulative deficit of $266 million and a net loss of $109 million for 2025.
A key milestone in the company’s capital‑raising journey was a $150 million Series B round that closed in March 2026. The round was led by asset manager Blue Owl Capital and included participation from existing investors 5AM Ventures, Foresite Capital and Alexandria Venture Investments, along with several new backers. The S‑1 states that the proceeds will support the late‑stage development of LTG‑101 and the execution of its clinical‑trial plan.
Latigo’s sodium‑channel blocker platform places it in a rapidly expanding segment of non‑opioid pain therapeutics. Vertex Pharmaceuticals, which received FDA approval in January 2025 for its Nav1.8‑selective drug suzetrigine (marketed as Journavx), has reported first‑year sales of about $90 million. Vertex is pursuing expansion of the product into chronic‑pain indications, although early results have been mixed. Eli Lilly entered the space in May 2025 by acquiring SiteOne Therapeutics for up to $1 billion; SiteOne’s lead asset, STC‑004, is in mid‑stage trials for moderate to severe acute pain.
LTG‑101 distinguishes itself by targeting a broader range of sodium channel subtypes involved in pain transmission. The S‑1 notes that the drug will be evaluated in a randomized, double‑blind, placebo‑controlled Phase 3 study enrolling patients with moderate to severe acute pain following surgery or injury. If the trial proves successful, Latigo plans to seek regulatory approval in the United States and potentially in other major markets.
The IPO filing arrives amid a wave of biotechnology listings. Six other companies—including cancer‑drug developer BlossomHill Therapeutics, heart‑disease specialist Braveheart Bio and genetic‑medicine firm Scribe Therapeutics—have announced plans to go public in the same quarter. Latigo’s prospectus indicates that proceeds from the offering will be used primarily to fund the Phase 3 trial of LTG‑101, to support ongoing pre‑clinical work, and to maintain working capital.
Investors and analysts will likely focus on the company’s financial trajectory, the competitive landscape of sodium‑channel blockers, and the timing of the Phase 3 trial. The S‑1 also highlights the broader pain‑medicine market, noting that the U.S. generates roughly 250 million pain‑related prescriptions annually—a figure that underscores the commercial potential of opioid‑free alternatives.
Latigo has not yet set a specific listing date, but Nasdaq typically requires a company to have a minimum of 1.1 million publicly held shares and a market value of at least $75 million at the time of listing. The filing includes a detailed plan for the use of proceeds and a schedule for the anticipated start of the Phase 3 trial.
In summary, Latigo Biotherapeutics is positioning itself as a small‑molecule competitor in the emerging sodium‑channel blocker pain‑drug market. The upcoming IPO will provide capital to advance its lead candidate, LTG‑101, into late‑stage testing. The next key milestones will be the initiation of the Phase 3 trial, the company’s Nasdaq listing, and the eventual regulatory review of the drug.
Founded in 2018 by venture‑capital firm Westlake BioPartners, the clinical‑stage biopharmaceutical focuses on non‑opioid pain medicines. Its flagship small‑molecule, LTG‑101, is a blocker of sodium ion channels and is slated to enter late‑stage (Phase 3) testing by the end of 2026 for moderate to severe acute pain. According to the S‑1, Latigo has raised roughly $322 million since its inception and, as of March 31, 2026, reported a cumulative deficit of $266 million and a net loss of $109 million for 2025.
A key milestone in the company’s capital‑raising journey was a $150 million Series B round that closed in March 2026. The round was led by asset manager Blue Owl Capital and included participation from existing investors 5AM Ventures, Foresite Capital and Alexandria Venture Investments, along with several new backers. The S‑1 states that the proceeds will support the late‑stage development of LTG‑101 and the execution of its clinical‑trial plan.
Latigo’s sodium‑channel blocker platform places it in a rapidly expanding segment of non‑opioid pain therapeutics. Vertex Pharmaceuticals, which received FDA approval in January 2025 for its Nav1.8‑selective drug suzetrigine (marketed as Journavx), has reported first‑year sales of about $90 million. Vertex is pursuing expansion of the product into chronic‑pain indications, although early results have been mixed. Eli Lilly entered the space in May 2025 by acquiring SiteOne Therapeutics for up to $1 billion; SiteOne’s lead asset, STC‑004, is in mid‑stage trials for moderate to severe acute pain.
LTG‑101 distinguishes itself by targeting a broader range of sodium channel subtypes involved in pain transmission. The S‑1 notes that the drug will be evaluated in a randomized, double‑blind, placebo‑controlled Phase 3 study enrolling patients with moderate to severe acute pain following surgery or injury. If the trial proves successful, Latigo plans to seek regulatory approval in the United States and potentially in other major markets.
The IPO filing arrives amid a wave of biotechnology listings. Six other companies—including cancer‑drug developer BlossomHill Therapeutics, heart‑disease specialist Braveheart Bio and genetic‑medicine firm Scribe Therapeutics—have announced plans to go public in the same quarter. Latigo’s prospectus indicates that proceeds from the offering will be used primarily to fund the Phase 3 trial of LTG‑101, to support ongoing pre‑clinical work, and to maintain working capital.
Investors and analysts will likely focus on the company’s financial trajectory, the competitive landscape of sodium‑channel blockers, and the timing of the Phase 3 trial. The S‑1 also highlights the broader pain‑medicine market, noting that the U.S. generates roughly 250 million pain‑related prescriptions annually—a figure that underscores the commercial potential of opioid‑free alternatives.
Latigo has not yet set a specific listing date, but Nasdaq typically requires a company to have a minimum of 1.1 million publicly held shares and a market value of at least $75 million at the time of listing. The filing includes a detailed plan for the use of proceeds and a schedule for the anticipated start of the Phase 3 trial.
In summary, Latigo Biotherapeutics is positioning itself as a small‑molecule competitor in the emerging sodium‑channel blocker pain‑drug market. The upcoming IPO will provide capital to advance its lead candidate, LTG‑101, into late‑stage testing. The next key milestones will be the initiation of the Phase 3 trial, the company’s Nasdaq listing, and the eventual regulatory review of the drug.
